Effect of physical activity on IGF-1 and IGFBP levels in the context of civilization diseases prevention

• Autorzy: Majorczyk M. , Smolag D.
• Języki publikacji: EN

Abstrakty

EN

Background. Insulin-like growth factor 1 (IGF-1) is known as somatomedin C. This polypeptide hormone is functionally and structurally similar to insulin. IGF-1 effects on tissue by the IGF-1R and the insulin-like growth factor-binding protein also known as IGFBP. Abnormal IGF-1 and IGFBP signaling are positively correlated with a high risk of selected civilization diseases development. Physical inactivity is a one of the main causes of majority of chronic diseases and it is associated with eg. IGF-1 and IGFBPs level. Objective. The aim of the study was to explanation the effect of physical activity on IGF-1 and its binding protein – IGFBPs concentration in the context of selected civilization diseases prevention. The review of clinical trial. Material and Methods. The review of articles had published in databases: MEDLINE, EMBASE, Scopus and Web of Science until December 2015. The selected prospective studies about the effect of exercise on IGF-1 level and its binding protein IGFBP in the context of selected civilization diseases prevention were collected. Results. The majority of the included studies indicate that mechanical loading is a key mechanism linking IGF-1/IGFBPs concentration and selected chronic diseases development. The duration and intensity of physical activity have a significant impact on IGF-1 and IGFBP serum. The highest concentration of IGF-1 in serum was after eccentric training. “Overtraining” increases unfavorable and unbound IGF-1 levels and contributes to the increased incidence of hormone-cancer and osteoarthritis. Conclusions. Irregularity of the GH/IGF-1 axis may affect on the development of rheumatic diseases, cardiovascular diseases (regulate cardiac growth and metabolism) and metabolic syndrome.

PL

Wprowadzenie. Insulinopodobny czynnik wzrostu 1 (IGF-1, insulin-like growth factor 1), zwany inaczej somatomedyną C. IGF-1 to hormon polipeptydowy, który funkcjonalnie i strukturalnie jest podobny do insuliny. IGF-1 oddziałuje na tkanki za pomocą receptora IGF-1R i białek wiążących IGFBP. Nieprawidłowości w produkcji IGF-1 i IGFBP są związane z wysokim ryzykiem rozwoju wielu chorób cywilizacyjnych. Brak aktywności fizycznej i związany z tym nieprawidłowy poziom krążącego IGF-1 przyczyniają się do rozwoju wielu przewlekłych chorób. Cel. Celem badania była próba wyjaśnienia wpływu zmian stężenia IGF-1 i jego białka wiążącego IGFBP pod wpływem aktywności fizycznej na profilaktykę chorób cywilizacyjnych na podstawie analizy badań klinicznych. Materiał i metody. Dokonano przeglądu artykułów opublikowanych do grudnia 2015 i zamieszczonych w bazach: MEDLINE, EMBASE, Scopus i Web of Science. Zebrano najnowsze badania prospektywne dotyczące znaczenia wysiłku fizycznego dla utrzymania prawidłowego poziomu IGF-1 i jego białka wiążącego IGFBP w kontekście profilaktyki wybranych chorób cywilizacyjnych. Wyniki. Większość analizowanych badań wskazuje, że aktywność fizyczna regulując stężenie IGF-1 i IGFBPs wpływa na rozwój wybranych chorób cywilizacyjnych. Długość trwania i intensywność wysiłku fizycznego ma istotne znaczenie dla stężenia IGF-1 i IGFBPs. Największy wzrost IGF-1 obserwuje się w wyniku escentrycznej pracy mięśni. Stan „przetrenowania” powoduje wzrost niekorzystnego, niezwiązanego IGF-1 w surowicy. Wzrost poziomu IGF-1 niezwiązanego przyczynia się do zwiększonej zachorowalności na nowotwory hormonozależne i chorobę zwyrodnieniową stawów. Wnioski. Nieprawidłowości osi GH/IGF-1 mogą wpływać na rozwój chorób reumatycznych, chorób układu krążenia i zespołu metabolicznego.

Słowa kluczowe

EN

physical activity; insulin-like growth factor 1; human disease; civilization disease; rheumatic disease; cardiovascular disease; prevention

• Wydawca: -
• Czasopismo: Roczniki Państwowego Zakładu Higieny
• Rocznik: 2016
• Tom: 67
• Numer: 2
• Opis fizyczny: p.105-111,ref.

Twórcy

autor

Majorczyk M.

• Faculty of Health Sciences, Jagiellonian University Collegium Medicum, Michalowskiego 12, 31-126 Krakow, Poland

autor

Smolag D.

• Faculty of Medicine, Jagiellonian University Collegium Medicum, Krakow, Poland

Bibliografia

• 1. Adamo M.L, Neuenschwander S, Le Roith D, Roberts C.T. Jr.: Structure, expression, and regulation of the IGF-I gene. Adv Exp Med Biol 1993; 343:1-11.
• 2. Alentinis B., Bhala A., DeAngelis T., Baserga R., Cohen P.: The human insulin like-growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol. Endocrinol. 1995;9:361-367
• 3. Amanaka Y., Fowlkes J.L., Wilson E.M., Rosenfeld R.G., Oh Y.: Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology 1999;140:1319- 1328.
• 4. Bayod S., Del Valle J., Canudas A.M.: Long-term treadmill exercises induces neuroprotective molecular changes in rat brain. J Appl Physiol 2011;111(5):1380- 90.
• 5. Björntorp E, Wickelgren R, Bjarnason R, Swanbeck G, Carlsson L.M., Lindahl A.: No evidence for involvement of the growth hormone/ insulin-like growth factor-1 axis in psoriasis. J Invest Dermatol 1997;109:661–665.
• 6. Bouillet T., Bigard X., Brami C. Chouahnia K., Copel L., Dauchy S., Delcambre C., Descotes J.M., Joly F., Lepeu G., Marre A., Scotte F., Spano J.P., Vanlemmens L., Zelek L.: Role of physical activity and sport in oncology: scientific commission of the National Federation Sport and Cancer CAMI. Crit Rev Oncol Hematol. 2015;94(1):74-86.
• 7. Buckwalter J.A., Lane N.E.: Athletics and osteoarthritis. Am. J. Sports Med. 1997;25(6): 873-881.
• 8. Burchardt P., Żurawski J., Nowak W.: Istotnie wyższe poziomy insulinopodobnego czynnika wzrostu 1 u pacjentów z zaawansowaną miażdżycą naczyń wieńcowych. Nowiny Lekarskie 2010;79(4):273–278.
• 9. Cassilhas R.C., Antunes H.K., Tufik S., de Mello M.T.: Mood, anxiety, and serum IGF-1 in elderly men given 24 weeks of high resistance exercise. Percept Mot Skills 2010;110(1):265-276.
• 10. Centers for Disease Control and Prevention Chronic Disease Prevention and Health Promotion. 2011. Available at: http://www.cdc.gov/chronicdisease/index. htm
• 11. Chao-Hung L., Tsung-Jung H., Wei-Wen K, Day C.H., Pai P.Y., Chung L.C., Liao P.H., Lin F.H., Wu E.T., Huang C.Y.: Exercise training enhanced SIRT1 longevity signaling replaces the IGF1 survival pathway to attenuate aging-induced rat heart apoptosis. Age (Dordr) 2014;36(5):9706.
• 12. Delafontaine P., Song Y-H., Li Y.: Expression, Regulation, and Function of IGF-1, IGF-1R, and IGF- 1 Binding Proteins in Blood Vessels. Arterioscler. Thromb. Vasc. Biol. 2004;24:435-444
• 13. Eliakim A, Nemet D, Cooper D.: Exercise, training, and the GH-IGF-I axis. In: The Endocrine System in Sports and Exercise, edited by Kraemer W.J., Rogol. Malden A.D., Blackwell A.M., 2005:165– 179.
• 14. Eliakim A., Brasel J.A., Mohan S., Wong W.L.T., Cooper D.M.: Increased physical activity and the growth hormone-IGF-I axis in adolescent males. Am J Psychol 1998; 275(1): 308–314.
• 15. Ferenc S., Daroszewska M., Sokołowski R., Zielińska I., Krzywińska O., Ciesielska N., Kozakiewicz M., Zukow W.: Influence of physical activity on the levels IGF-1 and IGFBPs at geriatric patients. Review of clinical trials. J. Health Science 2013;3(16):245-258.
• 16. Firth S.M, Baxter R.C.: Cellular actions of the insulinlike growth factor binding proteins. Endocr Rev 2002; 23:824-854.
• 17. Fontana L., Klein S., Holloszy J.O.: Long-term lowprotein, low-calorie diet and endurance exercise modulate metabolic factors associated with cancer risk. Am J Clin Nutr 2006; 84(6): 1456–1462.
• 18. Frisch H.: Growth hormone and body composition in athletes. J. Endocrinol Investig. 1999;22:106-109.
• 19. Goldspink G.: Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology 2005;20:232–238.
• 20. Gomez-Pinilla F., Vaynman S., Ying Z.: Brain-derived neurotrophic factor functions as a metabotrophin to mediate the effects of exercise on cognition. Eur J Neurosci 2008;28:2278–2287.
• 21. Grimberg A., Cohen P.: Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 2000;183:1–9.
• 22. Hawke T.J.: Muscle stem cells and exercise training. Exerc Sport Sci Rev 2005;33(2):63-8.
• 23. Heyn P., Abreu B.C., Ottenbacher K.J.: The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis. Arch Phys Med Rehabil 2004;85:1694–1704.
• 24. Hirsch C.S., Lumwalt R.E.: Injuries caused by physical agents. In: Kissane JM, editor. Anderson’s Pathology. Philadelphia, PA: Elesvier; 1996.
• 25. Huffman K.M., Sun J. L., Thomas L., Bales C.W., Califf R.M., Yates T., Davies M.J., Holman R.R., McMurray J.J., Bethel M.A., Tuomilehto J., Haffner S.M., Kraus W.E.: Impact of Baseline Physical Activity and Diet Behavior on Metabolic Syndrome in a Pharmaceutical Trial: Results from NAVIGATOR. Metabolism. 2014 April; 63(4): 554–561.
• 26. Hunt, T., Amato H.: Epiphyseal-plate fracture in an adolescent athlete. Athletic Therapy Today. 2003;8:34.
• 27. Jenkins P.J, Besser M.: Clinical perspective: acromegaly and cancer: a problem. J Clin Endocrinol Metab. 2001;86:2935–2941.
• 28. Jones L.W.: Cancer Prevention and Management Through Exercise and Weight Control. Psych-Oncol 2007;16(7):688.
• 29. Juul A., Scheike T., Davidsen M., Gyllenborg J., Jørgensen T.: Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002;106:939–944.
• 30. Kaaks R., Lukanova A.: Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001;60:91–106.
• 31. Kaplan R.C., McGinn A.P., Pollak M.N., Kuller L.H., Strickler H.D., Rohan T.E., Cappola A.R., Xue X., Psaty B.M.: Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab. 2007;92:1319–1325.
• 32. Karstoft K., Pedersen B.K.: Exercise and type 2 diabetes: focus on metabolism and inflammation. Immunol Cell Biol. 2015. doi: 10.1038/icb.2015.101. [Epub ahead of print]
• 33. Kaushal K., Heald A.H., Siddals K.W.: The impact of abnormalities in IGF and inflammatory systems on the metabolic syndrome. Diabetes Care. 2004;27(11):2682-8.
• 34. Koistinen H., Koistinen R., Selenius F., Ylikorkala O., Seppälä M.: Effect of marathon run on serum IGF-I and IGF-binding protein 1 and 3 levels. J Appl Physiol 1996;80(3):760–764.
• 35. Koziris L.P., Hickson R.C., Chatterton Jr R.T., Groseth R.T., Christie J.M., Goldflies D.G., Unterman T.G.: Serum levels of total and free IGF-I and IGFBP-3 are increased and maintained in long-term training. J Appl Physiol 1999; 86(4): 1436–1442.
• 36. Kraemer R.R., Durand R.J., Acevedo E.O., Johnson L.G., Kraemer G.R., Hebert E.P., Castracane V.D.: Rigorous Running Increases Growth Hormone and Insulin-Like Growth Factor-I without Altering Ghrelin. Experimental Biology and Medicine 2004;229(3):240–246.
• 37. Kraemer W.J., Marchitelli L., Gordon S.E., Harman E., Dziados J.E., Mello R., Frykman P., McCurry D., Fleck S.J.: Hormonal and growth factor responses to heavy resistance exercise protocols. J Appl Physiol 1999;69(4):1442–1450.
• 38. Llorens-Martin M, Torres-Aleman I, Trejo J.L.: Growth factors as mediators of exercise actions on the brain. Neuromolecular Med 2008;10:99–107.
• 39. Llorens-Martin M., Torres-Aleman I., Trejo J.L.: Exercise modulates insulin-like growth factor 1-dependent and -independent effects on adult hippocampal neurogenesis and behaviour. Mol Cell Neurosci 2010;44:109–117.
• 40. MacInnis R.J., English D.R., Hopper J.L., Haydon A.M., Gertig D.M., Giles G.G.: Body size and composition and colon cancer risk in men. Cancer Epidemiol Biomarkers Prev. 2004;13:553–559.
• 41. Markou K.B., Theodoropoulou A., Tsekouras A., Vagenakis A.G., Georgopoulos N.A. : Bone acquisition during adolescence in athletes. Ann N Y Acad Sci. 2010;1205:12-6
• 42. Matsakas A, Diel P.: The growth factor myostatin, a key regulator in skeletal muscle growth and homeostasis. Int J Sports Med 2005;26: 83–89.
• 43. McTiernan A., Sorensen B., Yasui Y., Tworoger S.S., Ulrich C.M., Irwin M.L., Rudolph R.E., Stanczyk F.Z., Schwartz R.S., Potter J.D.: No effect of exercise on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 in postmenopausal women: a 12-month randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2005; 14(4): 1020–1021.
• 44. Melikoglu M.A., Karatay S., Senel K., Akcay F.: Association between dynamic exercise therapy and IGF-1 and IGFBP-3 concentrations in the patients with rheumatoid arthritis. Rheumatol Int 2006;26:309–313.
• 45. Nemet D., Eliakim A.: Growth hormone-insulin-like growth factor-1 and inflammatory response to a single exercise bout in children and adolescents. Med Sport Sci. 2010;55:141-155.
• 46. Neri Serneri GG, Boddi M, Modesti PA, Cecioni I., Coppo M., Padeletti L., Michelucci A., Colella A., Galanti G.: Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes. Circ Res. 2001;89:977–98.
• 47. Nguyen, U.N., Mougin, F., Simon-Rigaud M.L., Rouillon J.D., Marguet P., Regnard J..: Influence of exercise duration on serum insulin-Iike growth factor and its binding proteins in athletes. Eur. J. Appl.Physiol, 1998;78:533-537.
• 48. Nindl B.C, Pierce J.R.: Insulin-like growth factor-I as a biomarker of health, fitness and training status. Med Sci Sports Exer 2010;42:39– 49.
• 49. Nindl B.C., Alemany J.A., Tuckow A.P., Kellogg M.D., Sharp M.A., Patton J.F.: Effects of exercise mode and duration on 24-h IGF-I system recovery responses. Med Sci Sports Exerc 2006;41:1261– 1270.
• 50. Nindl B.C., Tuckow A.P., Alemany J.A., Harman E.A., Rarick K.R., Staab J.S., Faupel M.L., Khosravi M.J.: Minimally invasive sampling of transdermal body fluid for the purpose of measuring insulin-like growth factor-I during exercise training. Diabetes Technol Ther2006; 8:244– 252.
• 51. Nishida Y., Matsubara T., Tobina T., Shindo M., Tokuyama K., Tanaka K., Tanaka H.: Effect of Low- Intensity Aerobic Exercise on Insulin-Like Growth Factor-I and Insulin-Like Growth Factor-Binding Proteins in Healthy Men. Intern J of Endocrin 2010; 2010. doi:10.1155/2010/452820.
• 52. Ohta M., Hirao N., Mori Y., Takigami C., Eguchi M., Tanaka H., Ikeda M., Yamato H.: Effects of bench step exercise on arterial stiffness in post-menopausal women: contribution of IGF-1 bioactivity and nitric oxide production. Growth Horm IGF Res. 2012;22(1):36-41.
• 53. Page J.H., Ma J., Pollak M., Manson J.E., Hankinson S.E.: Plasma Insulinlike Growth Factor 1 and Binding- Protein 3 and Risk of Myocardial Infarction in Women: A Prospective Study. Clin Chem. 2008;54(10):1682– 1688.
• 54. Poehlman E.T., Rosen C.J., Copeland K.C.: The influence of endurance training on insulin-like growth factor-I in older individuals. Metabolism 1994;43:1401–1405
• 55. Rajpathak S.N., McGinn A.P., Strickler H.D.: Insulinlike growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Horm IGF Res. 2008;18(2):166-73.
• 56. Renehan A.G, O’Connell J, O’Halloran D, Shanahan F, Potten C.S, O’Dwyer S.T, Shalet S.M.: Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Horm Metab Res. 2003;35:712–725.
• 57. Renehan A.G, Zwahlen M, Minder C., O’Dwyer S.T., Shalet S.M., Egger M.: Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346–1353.
• 58. Rian A. S Ttreuth M. S Rubin M. A., Miller J.P., Nicklas B.J., Landis D.M., Pratley R.E., Libanati C.R., Gundberg C.M, Hurley B.F.: Effects of strength training on bone mineral density: hormonal and bone turnover relationship. Journal of Applied Physiology 1994;77(4):1678-1684.
• 59. Ruidavets J.B., Luc G., Machez E., Genoux A.L., Kee F., Arveiler D., Morange P., Woodside J.V., Amouyel P., Evans A., Ducimetière P., Bingham A., Ferrières J., Perret B.: Effects of insulin-like growth factor 1 in preventing acute coronary syndromes: The PRIME study. Atherosclerosis 2011;218:464–469, doi: 10.1016/j. atherosclerosis.2011.05.034.
• 60. Salisbury T.B., Tomblin J.K.: Insulin/Insulin-Like Growth Factors in Cancer: New Roles for the Aryl Hydrocarbon Receptor, Tumor Resistance Mechanisms, and New Blocking Strategies. Front Endocrinol (Lausanne). 2015;6:12.
• 61. Schmitz K.H., Ahmed R.L., Yee D.: Effects of a 9-month strength training interventions on insulin, insulin-like growth factor (IGF-I), IGF-binding protein (IGFBP-1) and IGFBP-3 in 30–50-year old women. Cancer Epidemiol Biomarkers Prev 2002;11:1597– 1604.
• 62. Schwarz A. J., Brasel J. A., Hintz R. L., Mohan S., Cooper D. M.: Acute effect of brief low- and highintensity exercise on circulating insulin-like growth factor (IGF), I, II, and IGF-binding protein-3 and its proteolysis in young healthy men. J. Clin. Endocrinol. Metab. 1996;81:3492–3497.
• 63. Simons C.C., Schouten L.J., Godschalk R.W., van Engeland M., van den Brandt P.A., van Schooten F.J., Weijenberg M.P.: Genetic Variants in the Insulin-like Growth Factor Pathway and Colorectal Cancer Risk in the Netherlands Cohort Study. Sci Rep. 2015;5:14126.
• 64. Snow C.M., Rosen C.J., Robinson T.L.: Serum IGF-I is higher in gymnasts than runners and predicts bone and lean mass. Med Sci Sports Exerc. 2000;32(11):1902- 1907.
• 65. Succurro E., Andreozzi F., Sciacqua A., Hribal M.L., Perticone F., Sesti G.: Reciprocal Association of Plasma IGF-1 and Interleukin-6 Levels With Cardiometabolic Risk Factors in Nondiabetic Subjects. Diabetes Care. 2008;31(9):1886-8.
• 66. Sukhanov S., Higashi Y., Shai S.Y., Vaughn C., Mohler J., Li Y., Song Y.H., Titterington J., Delafontaine P.: IGF- 1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27(12):2684-90.
• 67. Thune I., Furberg A.S.: Physical activity and cancer risk: dose-response and cancer, all sites and sitespecific. Medicine and Science in Sports and Exercise 2001;33(6):530–550.
• 68. Tyler J. A.: IGF-1 can decrease degradation and promote synthesis of proteoglycan in cartilage exposed to cytokines. Biochem J 1989;260:543–549.
• 69. Vaessen N., Heutink P., Janssen J.A., Witteman J.C., Testers L., Hofman A., Lamberts S.W., Oostra B.A., Pols H.A., van Duijn C.M.: A polymorphism in the gene for IGF-1: Functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes. 2001;50:637–642.
• 70. Vainio H., Bianchini F.: IARC Handbook of Cancer Prevention: Weight Control and Physical Activity. IARC Press 2002; 2:2002.
• 71. Wakai K., Watanabe Y., Inaba Y., Tajima K., Nakachi K., Tamakoshi A.; JACC Study Group: Time spent walking or exercising and blood levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3): a large-scale cross-sectional study in the Japan collaborative cohort study. As Pac J Cancer Prev 2009;10:23–27.
• 72. Wu Y., Yakar S., Zhao L., Hennighausen L., LeRoith D.: Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 2002;62(4):1030-1035.
• 73. Yilmaz D, Ersoy B, Bilgin E., Gümüşer G., Onur E., Pinar E.D.: Bone mineral density in girls and boys at different pubertal stages: relation with gonadal steroids, bone formation markers, and growth parameters. J Bone Miner Metab 2005;23:476–482.